07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Galena Biopharma, MD Anderson Cancer Center, U.S. Department of Defense cancer news

The Department of Defense awarded the cancer center an undisclosed grant to fund a Phase II trial with Galena's NeuVax nelipepimut-S to prevent recurrence in breast cancer patients overexpressing epidermal growth factor receptor 2 (...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Dr. Reddy's, Galena Biopharma deal

Galena granted Dr. Reddy's exclusive rights to develop and commercialize NeuVax nelipepimut-S to treat breast and gastric cancer in India. Dr. Reddy's is responsible for conducting a Phase II trial in gastric cancer, which is...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Clinical News

Nelipepimut-S: Phase IIb started

Galena disclosed in its 2012 earnings that investigators began a single-blind, placebo-controlled Phase IIb trial to compare intradermal NeuVax plus Herceptin trastuzumab given every 3 weeks for 1 year vs. Herceptin plus granulocyte macrophage colony-stimulating...
02:33 , Dec 18, 2012 |  BC Extra  |  Financial News

Galena Biopharma planning follow-on

Galena Biopharma Inc. (NASDAQ:GALE) said it is planning a follow-on underwritten by Piper Jaffray. Galena's NeuVax is in the Phase III PRESENT trial to prevent recurrence of early stage, node-positive breast cancer. NeuVax is a...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

Galena Biopharma, Leica Microsystems deal

Leica's histopathology division Leica Biosystems will develop a companion diagnostic using its Bond Oracle HER2 IHC System to aid in selecting breast cancer patients to enroll in the ongoing Phase III PRESENT trial of Galena's...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

NeuVax: Phase III started

Galena disclosed in its 4Q11 earnings that in January it began the double-blind, international Phase III PRESENT trial evaluating NeuVax vs. Leukine sargramostim in about 700 patients with operable early-stage, node-positive breast cancer with low...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Galena Biopharma cancer, dermatology news

RXi Pharmaceuticals Corp. changed its named to Galena Biopharma Inc. and said it will separate its cancer and RNAi assets into two public companies. The first - which will be named Galena - will develop...
00:26 , Sep 27, 2011 |  BC Extra  |  Company News

RXi to separate RNAi, cancer assets

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said Monday it will separate its cancer and RNAi assets into two public companies. The first -- named Galena Biopharma Inc. -- will develop cancer vaccines, including NeuVax and a recently...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

RXi Pharmaceuticals, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. deal

RXi acquired patent rights from the foundation to develop and commercialize NeuVax for use in combination with Herceptin trastuzumab and in low-to-intermediate HER2-positive breast cancer patients not eligible for Herceptin treatment. RXi gained NeuVax through...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Company News

Apthera, RXi Pharmaceuticals deal

RXi completed its previously announced acquisition of cancer company Apthera, in a stock deal valued at $6.1 million, based on RXi's close of $1.28 on April 13, the day before the deal closed (see BioCentury,...